Clinical Trial Search

Primary: Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy — 11 Participants

Primary: Event-Free Survival Probability During the 5 Years After Transplant — 0.692 Probability

Primary: Adverse Events — 36 adverse events

Primary: Progression Free Survival — 7.6; 16.4 weeks

Primary: Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations From Samples Collected Pre-dose and at Different Time Points…

Primary: Time to Tumor Progression — 3.5 months

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6 — 7.24; -0.43; 3.8 Mean letter change in BCVA

Primary: The Percentage of Desensitized Participants as Measured by the Ability to Consume at Least 4443 mg of Wheat Protein During a 7443 mg Wheat Protein Oral Food Challenge…

Primary: Change From Baseline in Urinary Albumin Excretion — 50.5; -28.13; -4.5; 96.6 mg/g

Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…

Primary: Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity — 96; 75; 84; 93 percent wakefulness — p=0.01

Primary: Objective Response Rate — 71.2 Percentage of participants

Primary: Lactate Levels — 2; 2.0 mmol/L

Primary: Overall Survival at One Year — 19 Participants

Primary: Change From Baseline to Post-testing (After Max. 12 Days) on the Part/Whole Identity Test (LFI Skills Battery) — 3.30; 3.17 change in percent correct